South Asian Journal of Cancer, Table of Contents CC BY-NC-ND 4.0 · South Asian J Cancer 2014; 03(01): 083-086DOI: 10.4103/2278-330X.126553 THE GREAT DEBATE: FOR IMATINIB AS THE FIRST LINE TKI CHOICE FOR CML Is imatinib still the best choice as first-line oral TKI Shweta Bansal Department of Pediatric Oncology, Asian Institute of Oncology, K J Somaiya Hospital, Sion, Mumbai, Maharashtra › Author Affiliations Recommend Article Abstract PDF Download PDF (351 kb) References References 1 Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008;112:4808-17. 2 Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology. Blood 1999;94:1517-36. 3 O′Brien SG, Guilhot Fo, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004. 4 Deininger M, O′Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, et al. International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114:1126. 5 Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-35. 6 Kantarjian HM, Hochhaus A, Saglio G, Souza CD, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12:841-51. 7 Kantarjian HM, Kim DW, Issaragrisil S, Clark RE, Reiffers J, Nicolini FE, et al. Enestnd 4-Year (y) Update: Continued superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood 2012;120:1676. 8 Hochhaus A, Hughes TP, Saglio G, Guilhot F, Al-Ali HK, Rosti G, et al. Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) based on early molecular response and factors associated with early response: 4-Year follow-up data from Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients). Blood 2012;120:167. 9 Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70. 10 National Institute for health and clinical excellence (NICE). Dasatinib, nilotinib and standard dose Imatinib for first line treatment of chronic myeloid leukemia (part review of technology appraisal guidance 70), issued April 2012. NICE technology appraisal guidance 251. Available from: http://www: guidance.nice.org.uk/ta251. [Last accessed on 2013 Dec 10]. 11 Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, et al. A randomized trial of dasatinib 100mg versus Imatinib 400mg in newly diagnosed chronic phase chronic myeloid leukemia. Blood 2012;120:3898-905. 12 Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011;86:533-9. 13 Rea D, Gautier JF, Breccia M,et al. Incidence of hyperglycemia by 3 years in patients (Pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib (NIL) or imatinib (IM) in ENESTnd. Blood 2012;120:1686. 14 Guilhot F, Kantarjian H, Shah NP, Hochhaus A, Bradley-Garelik MB, Dejardin D, et al. Dasatinib (Versus Imatinib) In Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of Safety and Efficacy by Use of Baseline Medications In the DASISION Trial. Blood 2010;116:2295. 15 Montani D, Bergot E, Gunther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012;125:2128-37. 16 Hochhaus A, Saglio G, Larson RA, Kim DW, Etienne G, Rosti G, et al. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2013;121:3703-8. 17 Shah N, Kantarjian H, Hochhaus A, Cortes JE, Bradley-Garelik MB, Zhu C, et al. Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up. Blood 2010;116:206. 18 Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381-8. 19 Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperly JF, et al. European leukemia net recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872-84. 20 National comprehensive cancer network guidelines version 2.2012. Available from: http://Www.Nccn.Org/Professionals/Physician-Gls/Pdf/Cml.Pdf. [Last accessed on 2013 Dec 10].
